{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:09:39Z","timestamp":1792206579777,"version":"4.4.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"Importance<\/jats:title>Use of medications for attention-deficit\/hyperactivity disorder (ADHD) during pregnancy is increasing in the US. Whether exposure to these medications in utero impacts the risk of neurodevelopmental disorders in children is uncertain.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the association of childhood neurodevelopmental disorders with in utero exposure to stimulant medications for ADHD.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study included health care utilization data from publicly insured (Medicaid data from 2000 to 2018) and commercially insured (MarketScan Commercial Claims Database data from 2003 to 2020) pregnant individuals aged 12 to 55 years in the US with enrollment from 3 months prior to pregnancy through 1 month after delivery, linked to children. Children were monitored from birth until outcome diagnosis, disenrollment, death, or end of the study (December 2018 for Medicaid and December 2020 for MarketScan).<\/jats:p><\/jats:sec>Exposures<\/jats:title>Dispensing of amphetamine\/dextroamphetamine or methylphenidate in the second half of pregnancy.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Autism spectrum disorder, ADHD, and a composite of any neurodevelopmental disorder were defined using validated algorithms. Hazard ratios were estimated comparing amphetamine\/dextroamphetamine and methylphenidate to no exposure.<\/jats:p><\/jats:sec>Results<\/jats:title>The publicly insured cohort included 2\u202f496\u202f771 stimulant-unexposed, 4693 amphetamine\/dextroamphetamine-exposed, and 786 methylphenidate-exposed pregnancies with a mean (SD) age of 25.2 (6.0) years. The commercially insured cohort included 1\u202f773\u202f501 stimulant-unexposed, 2372 amphetamine\/dextroamphetamine-exposed, and 337 methylphenidate-exposed pregnancies with a mean (SD) age of 31.6 (4.6) years. In unadjusted analyses, amphetamine\/dextroamphetamine and methylphenidate exposure were associated with a 2- to 3-fold increased risk of the neurodevelopmental outcomes considered. After adjustment for measured confounders, amphetamine\/dextroamphetamine exposure was not associated with any outcome (autism spectrum disorder: hazard ratio [HR], 0.80; 95% CI, 0.56-1.14]; ADHD: HR, 1.07; 95% CI, 0.89-1.28; any neurodevelopmental disorder: HR, 0.91; 95% CI, 0.81-1.28). Methylphenidate exposure was associated with an increased risk of ADHD (HR, 1.43; 95% CI, 1.12-1.82]) but not other outcomes after adjustment (autism spectrum disorder: HR, 1.06; 95% CI, 0.62-1.81; any neurodevelopmental disorder: HR, 1.15; 95% CI, 0.97-1.36). The association between methylphenidate and ADHD did not persist in sensitivity analyses with stricter control for confounding by maternal ADHD.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings in this study suggest that amphetamine\/dextroamphetamine and methylphenidate exposure in utero are not likely to meaningfully increase the risk of childhood neurodevelopmental disorders.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2023.5073","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T16:00:56Z","timestamp":1706112056000},"page":"477","source":"Crossref","is-referenced-by-count":34,"title":["Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children"],"prefix":"10.1001","volume":"81","author":[{"given":"Elizabeth A.","family":"Suarez","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey"},{"name":"Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Bateman","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Hernandez-Diaz","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreen","family":"Straub","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[{"name":"Lurie Center for Autism, Massachusetts General Hospital, Lexington"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Wisner","sequence":"additional","affiliation":[{"name":"The Asher Center for the Study and Treatment of Depressive Disorders, Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Page B.","family":"Pennell","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Lester","sequence":"additional","affiliation":[{"name":"Center for the Study of Children at Risk, Warren Alpert Medical School of Brown University and Women & Infants Hospital, Providence, Rhode Island"},{"name":"Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, Rhode Island"},{"name":"Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mogun","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista F.","family":"Huybrechts","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"yoi230103r1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12402-016-0208-3","article-title":"The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys.","volume":"9","author":"Fayyad","year":"2017","journal-title":"Atten Defic Hyperact Disord"},{"key":"yoi230103r2","doi-asserted-by":"publisher","first-page":"04009","DOI":"10.7189\/jogh.11.04009","article-title":"The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis.","volume":"11","author":"Song","year":"2021","journal-title":"J Glob Health"},{"issue":"2","key":"yoi230103r3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/1087054717698815","article-title":"Prevalence of ADHD in publicly insured adults.","volume":"22","author":"Zhu","year":"2018","journal-title":"J Atten Disord"},{"issue":"7","key":"yoi230103r4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1185\/03007995.2014.901940","article-title":"Prevalence and incidence of adult attention deficit\/hyperactivity disorder in a large managed care population.","volume":"30","author":"Knight","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"sup2","key":"yoi230103r5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1185\/03007995.2011.603302","article-title":"Adult ADHD: prevalence of diagnosis in a US population with employer health insurance.","volume":"27","author":"Montejano","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"yoi230103r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14344","article-title":"Trends in the prevalence and incidence of attention-deficit\/hyperactivity disorder among adults and children of different racial and ethnic groups.","volume":"2","author":"Chung","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"yoi230103r7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/1087054716688534","article-title":"Diagnosis and treatment of ADHD in the United States: update by gender and race.","volume":"24","author":"Fairman","year":"2020","journal-title":"J Atten Disord"},{"issue":"10","key":"yoi230103r8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","article-title":"Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.","volume":"5","author":"Raman","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"yoi230103r9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.15585\/mmwr.mm6702a3","article-title":"Attention-deficit\/hyperactivity disorder medication prescription claims among privately insured women aged 15-44 years - United States, 2003-2015.","volume":"67","author":"Anderson","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"yoi230103r10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/pds.v24.2","article-title":"Increasing use of ADHD medications in pregnancy.","volume":"24","author":"Louik","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"yoi230103r11","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1080\/03007995.2021.1968814","article-title":"Treatment patterns among adults with attention-deficit\/hyperactivity disorder in the United States: a retrospective claims study.","volume":"37","author":"Schein","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"yoi230103r12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ntt.2015.07.006","article-title":"Developmental and behavioral consequences of prenatal methamphetamine exposure: a review of the Infant Development, Environment, and Lifestyle (IDEAL) study.","volume":"51","author":"Smith","year":"2015","journal-title":"Neurotoxicol Teratol"},{"issue":"3","key":"yoi230103r13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/ADM.0000000000000391","article-title":"Effect of methamphetamine hydrochloride on pregnancy outcome: a systematic review and meta-analysis.","volume":"12","author":"Kalaitzopoulos","year":"2018","journal-title":"J Addict Med"},{"issue":"7","key":"yoi230103r14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40263-020-00728-2","article-title":"Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review.","volume":"34","author":"Li","year":"2020","journal-title":"CNS Drugs"},{"issue":"5","key":"yoi230103r15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1055\/s-0032-1304818","article-title":"Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes.","volume":"29","author":"Shah","year":"2012","journal-title":"Am J Perinatol"},{"issue":"1","key":"yoi230103r16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ntt.2010.10.004","article-title":"Motor and cognitive outcomes through three years of age in children exposed to prenatal methamphetamine.","volume":"33","author":"Smith","year":"2011","journal-title":"Neurotoxicol Teratol"},{"issue":"4","key":"yoi230103r17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1542\/peds.2011-2209","article-title":"Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age.","volume":"129","author":"LaGasse","year":"2012","journal-title":"Pediatrics"},{"key":"yoi230103r18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jpeds.2015.11.070","article-title":"School-aged outcomes following prenatal methamphetamine exposure: 7.5-year follow-up from the infant development, environment, and lifestyle study.","volume":"170","author":"Eze","year":"2016","journal-title":"J Pediatr"},{"key":"yoi230103r19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.euroneuro.2021.01.003","article-title":"Maternal ADHD medication use during pregnancy and the risk of ADHD in children: importance of genetic predispositions and impact of using a sibling analysis.","volume":"44","author":"Lemelin","year":"2021","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"yoi230103r20","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41380-023-01992-6","article-title":"In utero exposure to ADHD medication and long-term offspring outcomes.","volume":"28","author":"Bang Madsen","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"6","key":"yoi230103r21","doi-asserted-by":"publisher","first-page":"e67405","DOI":"10.1371\/journal.pone.0067405","article-title":"Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations.","volume":"8","author":"Palmsten","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"yoi230103r22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/npp.2009.115","article-title":"Normal development of brain circuits.","volume":"35","author":"Tau","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"yoi230103r23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1002\/pds.v30.12","article-title":"Validity of claims-based algorithms to identify neurodevelopmental disorders in children.","volume":"30","author":"Straub","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"yoi230103r24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamapsychiatry.2021.3815","article-title":"Neurodevelopmental disorders among publicly or privately insured children in the United States.","volume":"79","author":"Straub","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"20","key":"yoi230103r25","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1001\/jama.2023.6078","article-title":"Autism prevalence has been on the rise in the US for decades\u2014and that\u2019s progress.","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"yoi230103r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0771","article-title":"Racial\/ethnic disparities in the prevalence and trends of autism spectrum disorder in US children and adolescents.","volume":"4","author":"Yuan","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"yoi230103r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0321","article-title":"Racial disparities in diagnosis of attention-deficit\/hyperactivity disorder in a US national birth cohort.","volume":"4","author":"Shi","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"25","key":"yoi230103r29","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.v28:25","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"2","key":"yoi230103r30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent.","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"issue":"2","key":"yoi230103r31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on P values: context, process, and purpose.","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"issue":"1","key":"yoi230103r32","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights.","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"key":"yoi230103r33","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"yoi230103r34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jclinepi.2011.09.002","article-title":"Tradeoffs between accuracy measures for electronic health care data algorithms.","volume":"65","author":"Chubak","year":"2012","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"yoi230103r35","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamainternmed.2022.0375","article-title":"Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study.","volume":"182","author":"Straub","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"11","key":"yoi230103r36","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/jamainternmed.2022.4268","article-title":"Association of antidepressant use during pregnancy with risk of neurodevelopmental disorders in children.","volume":"182","author":"Suarez","year":"2022","journal-title":"JAMA Intern Med"},{"key":"yoi230103r28","unstructured":"US Department of Agriculture\u2019s Economic Research Service. County-level data sets. Accessed March 18, 2020. Available from: https:\/\/www.ers.usda.gov\/data-products\/county-level-data-sets\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2814277\/jamapsychiatry_suarez_2024_oi_230103_1713287693.07772.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T15:28:05Z","timestamp":1714577285000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2814277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.5073","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}